ImmunityBio’s Bladder Cancer Immunotherapy gets an FDA Approval
News Source:- >> | Image Source:- >> ImmunityBio announced that the U.S. Food and Drug Administration has accepted its Biologics License Application (BLA) for N-803, a specific form of bladder cancer. N-803 is an antibody cytokine fusion protein. The BLA is for the use of the drug with Bacillus...